|
74 Companies |
|
57 Products |
|
57 Products |
|
42 Mechanisms of Action |
|
2 Trials |
|
680 News |
|
| «12345678910111213...1314» |
- Enrollment change, Trial withdrawal: UARK 2009-99 A Non-interventional Observational Study of Infectious Complications in Cancer Patients (clinicaltrials.gov) - Mar 5, 2015
P=N/A, N=0, Withdrawn, Sponsor: University of Arkansas
N=600 --> 0 | Recruiting --> Withdrawn
- |||| thimerosal (BTL-TML) / Beech Tree Labs
Trial completion, Enrollment change: Evaluation of Cold Sore Treatments on Ultra Violet (UV) Induced Cold Sores (clinicaltrials.gov) - Mar 5, 2015
P2, N=305, Completed, Sponsor: Beech Tree Labs, Inc.
N=600 --> 0 | Recruiting --> Withdrawn Active, not recruiting --> Completed | N=250 --> 305
- || Enrollment closed: Bihar Evaluation of Social Franchising and Telemedicine (clinicaltrials.gov) - Feb 27, 2015
P=N/A, N=106380, Active, not recruiting, Sponsor: Duke University
Active, not recruiting --> Completed | N=250 --> 305 Enrolling by invitation --> Active, not recruiting
- Zyclara (imiquimod) / Mochida, Viatris, Bausch Health
Enrollment closed, Enrollment change, Trial primary completion date: VRAIE: Comparison of Five Treatments in Patients With Plantar Warts (clinicaltrials.gov) - Feb 26, 2015
P4, N=358, Active, not recruiting, Sponsor: Assistance Publique - H
Enrolling by invitation --> Active, not recruiting Recruiting --> Active, not recruiting | N=660 --> 358 | Trial primary completion date: Apr 2015 --> Jan 2015
- Olorofim (orotomide) / F2G
Enrollment open, Trial primary completion date: F901318 Multiple Ascending Dose Study (clinicaltrials.gov) - Feb 20, 2015
P1, N=72, Recruiting, Sponsor: F2G Ltd.
Recruiting --> Active, not recruiting | N=660 --> 358 | Trial primary completion date: Apr 2015 --> Jan 2015 Not yet recruiting --> Recruiting | Trial primary completion date: Aug 2015 --> Nov 2015
- | Trial completion: Replacement of Insecticides to Control Visceral Leishmaniasis (VL) (clinicaltrials.gov) - Feb 19, 2015
P3, N=3600, Completed, Sponsor: International Centre for Diarrhoeal Disease Research, Bangladesh
Not yet recruiting --> Recruiting | Trial primary completion date: Aug 2015 --> Nov 2015 Recruiting --> Completed
- Trial completion, Enrollment change, Trial primary completion date: ERNIE2: Optimising Diagnosis and Antibiotic Prescribing for Acutely Ill Children in Primary Care (clinicaltrials.gov) - Feb 19, 2015
P=N/A, N=8962, Completed, Sponsor: Katholieke Universiteit Leuven
Recruiting --> Completed Recruiting --> Completed | N=6000 --> 8962 | Trial primary completion date: Jan 2014 --> Dec 2014
- | Stelara (ustekinumab) / J&J
Trial completion: A Proof of Concept Study to Evaluate the Effectiveness of Ustekinumab in Hidradenitis Suppurativa (clinicaltrials.gov) - Feb 13, 2015
P2, N=20, Completed, Sponsor: University Medical Centre Groningen
Recruiting --> Completed | N=6000 --> 8962 | Trial primary completion date: Jan 2014 --> Dec 2014 Active, not recruiting --> Completed
- ||||| Zeven (dalbavancin) / RaQualia, AbbVie
Enrollment closed: Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections (clinicaltrials.gov) - Feb 12, 2015
P3, N=698, Active, not recruiting, Sponsor: Durata Therapeutics, Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| Trial completion: Evaluate Safety and Efficacy of Naftifine Hydrochloride Gel 2% and Naftin® Gel 2% in Tinea Pedis (clinicaltrials.gov) - Feb 8, 2015
P1, N=690, Completed, Sponsor: Taro Pharmaceuticals USA
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||| CLS003 / Maruho
Enrollment open, P2 data: A Phase 2 Efficacy Study of CLS003 ICVT in Subjects With Cutaneous Warts. (clinicaltrials.gov) - Feb 6, 2015
P2, N=80, Recruiting, Sponsor: Cutanea Life Sciences, Inc.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Trial primary completion date: Registry for the Atopic Dermatitis Research Network (clinicaltrials.gov) - Feb 3, 2015
P=N/A, N=2600, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2014 --> Mar 2015
- Trial primary completion date, IO biomarker: Interferon Responses in Eczema Herpeticum (clinicaltrials.gov) - Feb 3, 2015
P=N/A, N=120, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Dec 2014 --> Mar 2015 Trial primary completion date: Aug 2015 --> Mar 2015
- |||| Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date: PIONEER (OLE): Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa (clinicaltrials.gov) - Feb 2, 2015
P3, N=540, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Trial primary completion date: Aug 2015 --> Mar 2015 Trial primary completion date: Jan 2015 --> Jul 2015
- |||| Sivextro (tedizolid) / Merck (MSD), Nabriva Therap
Trial primary completion date: Safety and Efficacy of BAY1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections (clinicaltrials.gov) - Jan 29, 2015
P3, N=150, Recruiting, Sponsor: Bayer
Trial primary completion date: Jan 2015 --> Jul 2015 Trial primary completion date: Feb 2016 --> Oct 2016
- | aztreonam / Generic mfg., vancomycin / Generic mfg., ceftaroline fosamil / Generic mfg.
Trial termination, Trial primary completion date: Evaluation of Ceftaroline Fosamil vs Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections. (clinicaltrials.gov) - Jan 29, 2015
P3, N=60, Terminated, Sponsor: AstraZeneca
Trial primary completion date: Feb 2016 --> Oct 2016 Recruiting --> Terminated | Trial primary completion date: Aug 2015 --> Jan 2015; Overall study status is changed to "Terminated" due to low enrollment
- || acyclovir / Generic mfg.
New P2/3 trial: Antiviral Prophylaxis in a Burn Population (clinicaltrials.gov) - Jan 29, 2015
P2/3, N=250, Recruiting, Sponsor: Southern Illinois University
- UB-621 / United BioPharma
New P1 trial: Study to Evaluate Safety, Tolerability, and Pharmacokinetics of UB-621 in Healthy Volunteers (clinicaltrials.gov) - Jan 28, 2015
P1, N=12, Not yet recruiting, Sponsor: United BioPharma
- ||| Enrollment open: Evaluation of the HSV 1 & 2 Assay in Specimens From Symptomatic Subjects (clinicaltrials.gov) - Jan 26, 2015
P=N/A, N=1900, Recruiting, Sponsor: Hologic, Inc.
Recruiting --> Terminated | Trial primary completion date: Aug 2015 --> Jan 2015; Overall study status is changed to "Terminated" due to low enrollment Not yet recruiting --> Recruiting
- | New P2 trial: Safety and Efficacy of NVXT Solution in Mild-to-Moderate Fungal Infection of the Toe Nail (clinicaltrials.gov) - Jan 22, 2015
P2, N=48, Recruiting, Sponsor: Taro Pharmaceuticals USA
- Trial primary completion date: Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients With Pentamidine: a Cohort Study (clinicaltrials.gov) - Jan 22, 2015
P3, N=72, Active, not recruiting, Sponsor: Institute of Tropical Medicine, Belgium
Not yet recruiting --> Recruiting Trial primary completion date: Aug 2014 --> Aug 2015
- Olorofim (orotomide) / F2G
New P1 trial: F901318 Multiple Ascending Dose Study (clinicaltrials.gov) - Jan 22, 2015
P1, N=72, Not yet recruiting, Sponsor: F2G Ltd.
- |||||| Xepi (ozenoxacin) / Maruho, Cipher, Ferrer International
Enrollment open: Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo (clinicaltrials.gov) - Jan 22, 2015
P3, N=412, Recruiting, Sponsor: Ferrer Internacional S.A.
Trial primary completion date: Aug 2014 --> Aug 2015 Not yet recruiting --> Recruiting
- | New P1/2 trial: A Phase I/II Double-blind Safety and Efficacy Evaluation of Nowarta110 in Patients With Plantar Warts (clinicaltrials.gov) - Jan 15, 2015
P1/2, N=120, Not yet recruiting, Sponsor: Nowarta Biopharma Inc
- cefazolin / Generic mfg., cephalexin / Generic mfg., probenecid / Generic mfg.
Trial completion, Enrollment change: Comparison of Intravenous Cefazolin Plus Oral Probenecid With Oral Cephalexin for the Treatment of Cellulitis (clinicaltrials.gov) - Jan 15, 2015
P2, N=201, Completed, Sponsor: Kelowna General Hospital
Not yet recruiting --> Recruiting Recruiting --> Completed | N=320 --> 201
- || Trial primary completion date, Combination therapy: MK0991 in Combination With Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis (0991-037) (clinicaltrials.gov) - Jan 13, 2015
P2, N=55, Completed, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Completed | N=320 --> 201 Trial primary completion date: Aug 2005 --> Sep 2004
- | Trial completion: A Clinical Investigation to Evaluate the Safety and Performance of a Treatment Kit for Ingrowing Toenail (clinicaltrials.gov) - Jan 13, 2015
P=N/A, N=36, Completed, Sponsor: Reckitt Benckiser Healthcare (UK) Limited
Trial primary completion date: Aug 2005 --> Sep 2004 Recruiting --> Completed
- ||||||| ceftaroline fosamil / Generic mfg.
Trial completion, Enrollment change: Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Skin Infections (clinicaltrials.gov) - Jan 13, 2015
P2/3, N=163, Completed, Sponsor: Cerexa, Inc.
Recruiting --> Completed Active, not recruiting --> Completed | N=270 --> 163
- Trial primary completion date: LEISH-F3 + GLA-SE and the LEISH-F3 + MPL-SE Vaccine (clinicaltrials.gov) - Jan 9, 2015
P1, N=48, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed | N=270 --> 163 Trial primary completion date: Sep 2014 --> Jan 2015
- ||| New P1 trial: Evaluate Safety and Efficacy of Naftifine Hydrochloride Gel 2% and Naftin® Gel 2% in Tinea Pedis (clinicaltrials.gov) - Jan 9, 2015
P1, N=690, Active, not recruiting, Sponsor: Taro Pharmaceuticals USA
- ||||| New P1/2 trial: Safety and Tolerability Study of Antimicrobial TheraGauze for Skin Abscess (clinicaltrials.gov) - Jan 8, 2015
P1/2, N=100, Not yet recruiting, Sponsor: Eastern Virginia Medical School
- | HSV vaccine (GEN-003) / Genocea, Shionogi
Enrollment open: Rollover Trial for Placebo Subjects Previously Enrolled Into GEN-003-002 Study (clinicaltrials.gov) - Jan 8, 2015
P2, N=45, Enrolling by invitation, Sponsor: Genocea Biosciences, Inc.
Trial primary completion date: Sep 2014 --> Jan 2015 Not yet recruiting --> Enrolling by invitation
- ||||| CLS003 / Maruho
New P2 trial, P2 data: A Phase 2 Efficacy Study of CLS003 ICVT in Subjects With Cutaneous Warts. (clinicaltrials.gov) - Jan 7, 2015
P2, N=80, Not yet recruiting, Sponsor: Cutanea Life Sciences, Inc.
- Trial primary completion date: A Randomized Controlled Trial of Inhaled Amphotericin B for Maintaining Remission in Allergic Bronchopulmonary Aspergillosis (clinicaltrials.gov) - Dec 30, 2014
P2/3, N=20, Recruiting, Sponsor: Postgraduate Institute of Medical Education and Research
Not yet recruiting --> Enrolling by invitation Trial primary completion date: May 2014 --> Jun 2015
- | voriconazole / Generic mfg.
Trial primary completion date: Voriconazole Versus Oral Steroids in Allergic Bronchopulmonary Aspergillosis (clinicaltrials.gov) - Dec 30, 2014
P2/3, N=50, Recruiting, Sponsor: Postgraduate Institute of Medical Education and Research
Trial primary completion date: May 2014 --> Jun 2015 Trial primary completion date: Jun 2014 --> Jun 2015
- itraconazole / Generic mfg.
Trial primary completion date, Monotherapy: Monotherapy of Itraconazole Versus Prednisolone in Allergic Bronchopulmonary Aspergillosis (clinicaltrials.gov) - Dec 30, 2014
P2/3, N=50, Recruiting, Sponsor: Postgraduate Institute of Medical Education and Research
Trial primary completion date: Jun 2014 --> Jun 2015 Trial primary completion date: Jun 2013 --> Jun 2015
- Trial primary completion date: Protocol TARC-ABPA (clinicaltrials.gov) - Dec 25, 2014
P=N/A, N=30, Recruiting, Sponsor: Nantes University Hospital
Trial primary completion date: Jun 2013 --> Jun 2015 Trial primary completion date: May 2017 --> Nov 2017
- | otesaconazole (VT-1161) / Mycovia Pharma
Trial completion: A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Moderate - Severe Interdigital Tinea Pedis (clinicaltrials.gov) - Dec 25, 2014
P2, N=50, Completed, Sponsor: Viamet Pharmaceuticals, Inc.
Trial primary completion date: May 2017 --> Nov 2017 Active, not recruiting --> Completed
- Trial completion, Trial primary completion date, IO biomarker: Diagnostic and Management Strategies for Invasive Aspergillosis (clinicaltrials.gov) - Dec 24, 2014
P=N/A, N=203, Completed, Sponsor: King's College Hospital NHS Trust
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Dec 2010 --> Dec 2011
- | gentamicin sulfate / Generic mfg.
Enrollment change, Trial primary completion date: Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama (clinicaltrials.gov) - Dec 19, 2014
P3, N=400, Recruiting, Sponsor: U.S. Army Medical Research and Materiel Command
Recruiting --> Completed | Trial primary completion date: Dec 2010 --> Dec 2011 N=300 --> 400 | Trial primary completion date: Jun 2015 --> Dec 2015
- gentamicin sulfate / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: WR 279,396 Open Label Treatment Protocol in Tunisia (clinicaltrials.gov) - Dec 19, 2014
P2, N=50, Terminated, Sponsor: U.S. Army Medical Research and Materiel Command
N=300 --> 400 | Trial primary completion date: Jun 2015 --> Dec 2015 N=120 --> 50 | Suspended --> Terminated | Trial primary completion date: Aug 2013 --> Jun 2012; This study was closed prematurely due study team travel restrictions.
- phenoxymethylpenicillin / Generic mfg., doxycycline / Generic mfg., amoxicillin / Generic mfg.
Trial completion: NorTick_EM: Comparing 3 Antibiotic Regimes for Erythema Migrans in General Practice (clinicaltrials.gov) - Dec 13, 2014
P4, N=225, Completed, Sponsor: Morten Lindbaek
N=120 --> 50 | Suspended --> Terminated | Trial primary completion date: Aug 2013 --> Jun 2012; This study was closed prematurely due study team travel restrictions. Active, not recruiting --> Completed
- ||| Trial initiation date: A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of Molluscum Contagiosum (clinicaltrials.gov) - Dec 10, 2014
P2, N=200, Not yet recruiting, Sponsor: ViroXis Corporation
Active, not recruiting --> Completed Initiation date: Jul 2014 --> Jan 2015
- | tigecycline / Generic mfg.
Phase classification: TIGER: Tygacil Drug Use Investigation (clinicaltrials.gov) - Dec 9, 2014
P4, N=100, Enrolling by invitation, Sponsor: Pfizer
Initiation date: Jul 2014 --> Jan 2015 Phase classification: P=N/A --> P4
- ||||| Zeven (dalbavancin) / RaQualia, AbbVie
Enrollment change: Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections (clinicaltrials.gov) - Dec 6, 2014
P3, N=698, Recruiting, Sponsor: Durata Therapeutics, Inc.
Phase classification: P=N/A --> P4 N=410 --> 698
- | HSV vaccine (GEN-003) / Genocea, Shionogi
New P2 trial: Rollover Trial for Placebo Subjects Previously Enrolled Into GEN-003-002 Study (clinicaltrials.gov) - Nov 24, 2014
P2, N=45, Not yet recruiting, Sponsor: Genocea Biosciences, Inc.
- Enrollment closed: Phase 1 LEISH-F3 + SLA-SE Vaccine Trial in Healthy Adult Volunteers (clinicaltrials.gov) - Nov 24, 2014
P1, N=39, Active, not recruiting, Sponsor: Infectious Disease Research Institute
N=410 --> 698 Recruiting --> Active, not recruiting
- ||| HSV vaccine (GEN-003) / Genocea, Shionogi
Enrollment closed: Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine (clinicaltrials.gov) - Nov 23, 2014
P2, N=315, Active, not recruiting, Sponsor: Genocea Biosciences, Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||| AMG 108 / AstraZeneca
Trial completion, Enrollment change: Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa (clinicaltrials.gov) - Nov 18, 2014
P2a, N=224, Completed, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=100 --> 224
- | Olorofim (orotomide) / F2G
Trial completion: F901318 Single Ascending Dose Study in Healthy Male Volunteers (clinicaltrials.gov) - Nov 12, 2014
P1, N=40, Completed, Sponsor: F2G Ltd.
Active, not recruiting --> Completed | N=100 --> 224 Recruiting --> Completed